Enable Injections and Incyte Forge Partnership to Advance Patient Care in Chronic Blood and Bone Marrow Conditions

Enable Injections, the developer of the enFuse wearable drug delivery system, has entered into a strategic partnership with Incyte Corporation to combine their technologies and improve patient care for certain chronic blood and bone marrow disorders. The collaboration, announced on October 27, 2025, focuses on Incyte's investigational mutant calreticulin selective monoclonal antibody treatment for essential thrombocythemia and myelofibrosis.

Partnership Details and Financial Implications

Under the terms of the agreement, Incyte will provide Enable Injections with an upfront technology access fee. Additional payments are structured around research and development milestones, commercial achievements, and a transfer price for the clinical and commercial supply of enFuse devices. While specific financial details were not disclosed, the deal represents a significant step for both companies in advancing their respective technologies and market positions.

The collaboration aims to leverage Enable Injections' enFuse system, which can deliver large volumes of both small-molecule and biologic medications subcutaneously. This technology offers patients a simpler alternative to intravenous administration, potentially improving treatment adherence and quality of life for those with chronic conditions.

Strategic Moves and Leadership Changes

This partnership aligns with Incyte's recent strategic shift under the leadership of Bill Meury, who assumed the role of President and CEO in June 2025. Meury, formerly of Karuna Therapeutics, has outlined a business development strategy focused on acquiring "derisked pre-revenue or revenue-stage opportunities." The collaboration with Enable Injections appears to be a step in this direction, potentially expanding Incyte's capabilities in drug delivery and patient care.

Meury expressed enthusiasm about the partnership, stating, "We're looking forward to partnering with Enable and combining our expertise to make advanced treatments more accessible and less burdensome for patients, while maintaining the high standards of safety and efficacy patients and providers expect."

Pipeline Prioritization and Future Directions

Concurrent with the Enable Injections partnership announcement, Incyte revealed significant changes to its drug development pipeline. The company has decided to discontinue its BET inhibitor program and halt work on its anti-CD122 drug, INCA034460. These decisions are part of Incyte's "ongoing pipeline prioritization efforts," suggesting a strategic realignment of resources towards more promising areas of research and development.

The focus on the mutant calreticulin selective monoclonal antibody treatment for essential thrombocythemia and myelofibrosis, combined with Enable Injections' innovative delivery system, indicates Incyte's commitment to addressing unmet needs in hematology and oncology. This approach may set the stage for future developments in targeted therapies for chronic blood and bone marrow disorders.